1. Home
  2. EOD vs CCCC Comparison

EOD vs CCCC Comparison

Compare EOD & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Global Dividend Opportunity Fund of Beneficial Interest

EOD

Allspring Global Dividend Opportunity Fund of Beneficial Interest

HOLD

Current Price

$5.98

Market Cap

252.4M

Sector

Finance

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.57

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOD
CCCC
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.4M
240.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EOD
CCCC
Price
$5.98
$2.57
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.50
AVG Volume (30 Days)
118.1K
1.7M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
9.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$30,108,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.73
$1.09
52 Week High
$4.71
$4.89

Technical Indicators

Market Signals
Indicator
EOD
CCCC
Relative Strength Index (RSI) 68.59 51.91
Support Level $5.58 $2.49
Resistance Level $5.89 $2.84
Average True Range (ATR) 0.07 0.19
MACD 0.02 0.00
Stochastic Oscillator 100.00 52.72

Price Performance

Historical Comparison
EOD
CCCC

About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest

Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: